The global medical in vitro diagnostic market has been undergoing increasingly complex changes and more intense competition in recent years. In China, this market pattern has changed particularly dramatically. To this end, multinational enterprises are also speeding up the adjustment of strategies to adapt to the new competitive environment in the market. On December 3, at the first “Sino-Swiss Innovation Day” event hosted by the Swiss Chamber of Commerce and Roche Diagnostics Suzhou, Roche Diagnostics announced the latest localization initiative: the company's first domestically produced real-time fluorescence quantitative PCR instrument, LCPRO, was officially launched in China. It is committed to continuing to empower local scientific research and innovation, meet the unmet needs of molecular laboratories, and benefit more Chinese patients. At the same time, in order to achieve efficient integration of resources and deep collaboration of capabilities, Roche also signed a contract with the Suzhou Center for Disease Prevention and Control, taking a key step in the strategy of accelerating the localization development of Roche's diagnosis.

The global medical in vitro diagnostic market has been undergoing increasingly complex changes and more intense competition in recent years. In China, this market pattern has changed particularly dramatically. To this end, multinational enterprises are also speeding up the adjustment of strategies to adapt to the new competitive environment in the market. On December 3, at the first “Sino-Swiss Innovation Day” event hosted by the Swiss Chamber of Commerce and Roche Diagnostics Suzhou, Roche Diagnostics announced the latest localization initiative: the company's first domestically produced real-time fluorescence quantitative PCR instrument, LCPRO, was officially launched in China. It is committed to continuing to empower local scientific research and innovation, meet the unmet needs of molecular laboratories, and benefit more Chinese patients. At the same time, in order to achieve efficient integration of resources and deep collaboration of capabilities, Roche also signed a contract with the Suzhou Center for Disease Prevention and Control, taking a key step in the strategy of accelerating the localization development of Roche's diagnosis.